Immunosuppression
Disease2 papers
- Humans1
- Animals1
Trial sponsors
National Taiwan University Hospital
2 trialsPhase 480 people
University Medical Center Groningen
1 trialPhase 4374 people
1 trialPhase 4278 people
1 trialPhase 4100 people
1 trialPhase 458 people
1 trialPhase 430 people
Deise de Boni Monteiro de Carvalho
1 trialPhase 430 people
Massachusetts General Hospital
1 trialPhase 417 people
Funding
National Cancer InstituteUS$848.5kNational Institute of Allergy and Infectious DiseasesUS$731.3k3 grants since 2022
Generating Exogenic Organs for Transplantation without the Use of Immunosuppression
National Institute of Allergy and Infectious DiseasesUniversity of MinnesotaUS$731.3k2022–2027
Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol
National Cancer InstituteWestern University of Health SciencesUS$322.5k2022–2027
National Cancer InstituteUniversity of PennsylvaniaUS$526k2025–2030
Latest
47Jianwei Shoutai Pills reduce uterine aging and pregnancy loss in aged mice
The herbal formula delayed thymic involution, restored regulatory T cell function, and improved maternal-fetal immune tolerance by altering metabolic…The herbal formula delayed thymic involution, restored regulatory T cell function, and improved maternal-fetal immune tolerance by altering metabolic signaling in aging female mice.
Objectively Measured Photoaging and Skin Cancer in Organ Transplant Recipients
Rapamycin slows pulmonary fibrosis by reducing lung epithelial cell senescence in mice
The immunosuppressant suppresses epithelial-mesenchymal transition and promotes p53 degradation via the SFN-MDM2 pathway to curb fibrotic lung…The immunosuppressant suppresses epithelial-mesenchymal transition and promotes p53 degradation via the SFN-MDM2 pathway to curb fibrotic lung disease.